Manchester Peptides gold M logoMANCHESTERPEPTIDES
24/7 enquiries
UK research catalogueThird-party COAsEvidence-led guides24/7 enquiries
Next Day Guaranteed Delivery
Manchester Peptides gold M logo

MANCHESTERPEPTIDES

Independent research catalogue · COAs and laboratory reports available where supplied

The Manchester Peptides reference centre

Explore the peptide research catalogue

Browse pens, vials, injectables and orals by name or format. Read the research guides and check which sample each laboratory report describes.

Browse all products View laboratory reports

Explore the collection

Pens & vials

View all products →
Retatrutide 30 mg Vial — Manchester Peptides packaging visualisation
Packaging visualisation

Vial · 30 mg

Retatrutide

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways.

£85
Product information

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.

Evidence and sources at a glance
Human evidence
Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
Regulatory context
Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.
Read the full evidence map
Related laboratory reports30 mg COA preview30 mg COA previewReports describe the tested samples; batch identity must be matched separately.
Lilly: current retatrutide research programmeRead the Retatrutide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View Retatrutide details
Retatrutide 40 mg Pen — supplied Manchester Peptides box artwork
Supplied packaging artwork

Pen · 40 mg

Retatrutide

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways.

£120
Product information
Manchester Peptides Retatrutide 40 mg pen box — supplied packaging artwork
Retatrutide · 40 mg · Pen — supplied packaging artwork. Open image to enlarge; the image is not independent proof of contents or batch identity.

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.

Evidence and sources at a glance
Human evidence
Randomised phase 2 evidence and reported phase 3 results are available. Check whether a particular result is a peer-reviewed publication or a sponsor announcement, and inspect its population and follow-up.
Regulatory context
Retatrutide is not currently an authorised UK medicine. Investigational status should never be presented as approval.
Read the full evidence map
Related laboratory reports40 mg COA previewReports describe the tested samples; batch identity must be matched separately.
Lilly: current retatrutide research programmeRead the Retatrutide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View Retatrutide details
Tirzepatide 40 mg Pen — supplied Manchester Peptides box artwork
Supplied packaging artwork

Pen · 40 mg

Tirzepatide

(Mounjaro is a licensed medicine containing tirzepatide)

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways.

£120
Product information
Manchester Peptides Tirzepatide 40 mg pen box — supplied packaging artwork
Tirzepatide · 40 mg · Pen — supplied packaging artwork. Open image to enlarge; the image is not independent proof of contents or batch identity.

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways. Authorised prescription versions have established clinical uses, but unlicensed research material is not equivalent to an approved medicine.

Evidence and sources at a glance
Human evidence
Multiple phase 3 trials and real-world use provide a much larger evidence base than is available for most catalogue peptides.
Regulatory context
Authorised tirzepatide medicines have approved indications and controlled supply routes; research material is not equivalent.
Read the full evidence map
NHS: tirzepatideRead the Tirzepatide research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View Tirzepatide details
GHK-Cu 100 mg Vial — Manchester Peptides packaging visualisation
Packaging visualisation

Vial · 100 mg

GHK-Cu

A naturally occurring copper-binding tripeptide researched in skin, extracellular-matrix and wound-repair biology.

£40
Product information

A naturally occurring copper-binding tripeptide researched in skin, extracellular-matrix and wound-repair biology. Studies explore collagen, elastin, tissue remodelling and hair-follicle pathways, with evidence varying by formulation and use.

Evidence and sources at a glance
Human evidence
Some topical and cosmetic studies exist, but formulation quality, scale and endpoints vary.
Regulatory context
Cosmetic ingredient use is not evidence that injectable GHK-Cu is an approved treatment.
Read the full evidence map
Related laboratory reports100 mg COA previewReports describe the tested samples; batch identity must be matched separately.
PubMed: topical GHK evidence reviewRead the GHK-Cu research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View GHK-Cu details
BPC-157 + TB-500 10 mg + 10 mg Set — Manchester Peptides packaging visualisation
Packaging visualisation

Vial set · 10 mg + 10 mg

BPC-157 + TB-500

A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research.

£65
Product information

A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research. Studies consider cell migration, inflammatory signalling and wound-repair pathways, but the combined ‘Wolverine’ format is not an approved clinical formulation.

Evidence and sources at a glance
Human evidence
Robust, replicated controlled human evidence for BPC-157 is absent, and the marketed blend itself lacks an established clinical evidence base.
Regulatory context
The combined product is not an approved UK medicine and should not be described as a proven injury treatment.
Read the full evidence map
PubMed: BPC-157 translational research reviewRead the BPC-157 + TB-500 research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View BPC-157 + TB-500 details
MOTS-C 40 mg Vial — Manchester Peptides packaging visualisation
Packaging visualisation

Vial · 40 mg

MOTS-C

A mitochondria-derived peptide studied as a signal connecting cellular stress, energy use and metabolic adaptation.

£55
Product information

A mitochondria-derived peptide studied as a signal connecting cellular stress, energy use and metabolic adaptation. Research explores mitochondrial function, insulin sensitivity and exercise-response pathways, although most intervention evidence remains preclinical.

Evidence and sources at a glance
Human evidence
Human work includes observational biology and early experimental research, not an established therapeutic evidence base.
Regulatory context
MOTS-C is not an approved medicine for metabolism, exercise performance or ageing.
Read the full evidence map
PubMed: MOTS-c research reviewRead the MOTS-C research guide →For research and reference purposes only. Listing a product does not establish suitability for medical use.
View MOTS-C details

Manchester, Stockport & UK delivery

Check delivery to your area

Browse the same pen and vial catalogue from Greater Manchester, Cheshire or elsewhere in the UK. The basket includes one £10 delivery charge. Confirm dispatch timing and postcode eligibility before relying on next-day arrival.

Start with a question

Research, made clearer.

All research guides →
01 / Foundations

What are peptides?

Understand the terminology, the molecular differences and why evidence matters.

Read the introduction ↗02 / Compare the science

Retatrutide vs Tirzepatide

Receptor targets, landmark studies and the limits of comparing separate trials.

Explore the comparison ↗03 / Check a document

Read a peptide COA

Work through a practical, interactive checklist for sample identity, methods and measured results.

Open the reading checklist ↗

Clear information. Visible limitations.

Know what the evidence actually says.

A catalogue label describes a supplied format. A study investigates a research question. A certificate records results for a named sample. Our reference centre connects them while keeping those distinctions clear.

Our sources and editorial standards ↗

Go deeper by name

Peptide research guides

What each peptide does →

Explore identity, research mechanisms, evidence levels and limitations, with sources you can follow.

The visual information series

One poster. One product.

Explore 12 individual information posters, from Retatrutide and Tirzepatide to GHK-Cu, Wolverine and KLOW. Open a poster, then follow its research guide for sources and context.

Browse the individual posters →
Manchester Peptides Retatrutide information poster

From our WhatsApp community

What our customers say

Read all 200 reviews →
Payment system very easy to navigate. Retatrutide and BPC have really helped, lost two stone already
MikeManchester
Definitely would use again. Retatrutide is working great for me
Sarah ThompsonLeeds
First class service every time. BPC and GHK-Cu have made a real difference
James WilsonBirmingham
Reviews